Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Oct;66(4):706–711. doi: 10.1038/bjc.1992.342

Significance of S-phase fraction and hormone receptor content in the management of young breast cancer patients.

O Stål 1, J Carstensen 1, T Hatschek 1, B Nordenskjöld 1
PMCID: PMC1977426  PMID: 1419611

Abstract

Tumours from 336 breast cancer patients under the age of 50 were analysed for hormone receptor content and by DNA flow cytometry. Sixty-six percent of the tumours were positive for estrogen receptors (ER), 60% were progesterone receptor (PR) positive and 42% showed DNA diploid profiles. DNA hypodiploid tumours were relatively frequent (7%), especially in patients aged 40 years or less (11%). S-phase fraction (SPF), with a mean of 10%, correlated significantly with receptor status, DNA ploidy, lymph node status, tumour size and age. With a median follow-up period of 34 months, the distant recurrence-free interval was independently predicted by lymph node status, tumour size, SPF and PR content. Amongst the 212 patients who had not received adjuvant systemic treatment, receptor status was, in addition to lymph node status and SPF, independently related to distant recurrence rate. A high SPF identified a subgroup with high recurrence rate, comprising approximately one third of the node-negative patients. Similarly, the one third of node-positive patients who had PR-positive tumours with a low S-phase fraction formed a subgroup with low recurrence rate. We conclude that hormone receptor assays and DNA flow cytometry should be useful tools in the management of breast cancer patients less than 50 years of age.

Full text

PDF
706

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baildam A. D., Zaloudik J., Howell A., Barnes D. M., Turnbull L., Swindell R., Moore M., Sellwood R. A. DNA analysis by flow cytometry, response to endocrine treatment and prognosis in advanced carcinoma of the breast. Br J Cancer. 1987 May;55(5):553–559. doi: 10.1038/bjc.1987.113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Baisch H., Göhde W., Linden W. A. Analysis of PCP-data to determine the fraction of cells in the various phases of cell cycle. Radiat Environ Biophys. 1975 Jun 13;12(1):31–39. doi: 10.1007/BF02339807. [DOI] [PubMed] [Google Scholar]
  3. Carter C. L., Allen C., Henson D. E. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989 Jan 1;63(1):181–187. doi: 10.1002/1097-0142(19890101)63:1<181::aid-cncr2820630129>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  4. Clark G. M., Dressler L. G., Owens M. A., Pounds G., Oldaker T., McGuire W. L. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med. 1989 Mar 9;320(10):627–633. doi: 10.1056/NEJM198903093201003. [DOI] [PubMed] [Google Scholar]
  5. Cornelisse C. J., van de Velde C. J., Caspers R. J., Moolenaar A. J., Hermans J. DNA ploidy and survival in breast cancer patients. Cytometry. 1987 Mar;8(2):225–234. doi: 10.1002/cyto.990080217. [DOI] [PubMed] [Google Scholar]
  6. Crowe J. P., Hubay C. A., Pearson O. H., Marshall J. S., Rosenblatt J., Mansour E. G., Hermann R. E., Jones J. C., Flynn W. J., McGuire W. L. Estrogen receptor status as a prognostic indicator for stage I breast cancer patients. Breast Cancer Res Treat. 1982;2(2):171–176. doi: 10.1007/BF01806453. [DOI] [PubMed] [Google Scholar]
  7. Ewers S. B., Baldetorp B., Killander D., Långström E. Flow cytometry DNA ploidy and number of cell populations in the primary breast cancer and their correlation to the prognosis. Acta Oncol. 1989;28(6):913–918. doi: 10.3109/02841868909092331. [DOI] [PubMed] [Google Scholar]
  8. Fernö M., Borg A., Sellberg G. Enzyme immuno assay of the estrogen receptor in breast cancer biopsy samples. A comparison with isoelectric focusing. Acta Radiol Oncol. 1986 May-Jun;25(3):171–175. doi: 10.3109/02841868609136398. [DOI] [PubMed] [Google Scholar]
  9. Fisher B., Costantino J., Redmond C., Poisson R., Bowman D., Couture J., Dimitrov N. V., Wolmark N., Wickerham D. L., Fisher E. R. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989 Feb 23;320(8):479–484. doi: 10.1056/NEJM198902233200802. [DOI] [PubMed] [Google Scholar]
  10. Godolphin W., Elwood J. M., Spinelli J. J. Estrogen receptor quantitation and staging as complementary prognostic indicators in breast cancer: a study of 583 patients. Int J Cancer. 1981 Dec;28(6):677–683. doi: 10.1002/ijc.2910280604. [DOI] [PubMed] [Google Scholar]
  11. Hatschek T., Fagerberg G., Stål O., Sullivan S., Carstensen J., Gröntoft O., Nordenskjöld B. Cytometric characterization and clinical course of breast cancer diagnosed in a population-based screening program. Cancer. 1989 Sep 1;64(5):1074–1081. doi: 10.1002/1097-0142(19890901)64:5<1074::aid-cncr2820640519>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  12. Hedley D. W., Rugg C. A., Gelber R. D. Association of DNA index and S-phase fraction with prognosis of nodes positive early breast cancer. Cancer Res. 1987 Sep 1;47(17):4729–4735. [PubMed] [Google Scholar]
  13. Héry M., Gioanni J., Lalanne C. M., Namer M., Courdi A. The DNA labelling index: a prognostic factor in node-negative breast cancer. Breast Cancer Res Treat. 1987;9(3):207–211. doi: 10.1007/BF01806381. [DOI] [PubMed] [Google Scholar]
  14. Kallioniemi O. P., Blanco G., Alavaikko M., Hietanen T., Mattila J., Lauslahti K., Lehtinen M., Koivula T. Improving the prognostic value of DNA flow cytometry in breast cancer by combining DNA index and S-phase fraction. A proposed classification of DNA histograms in breast cancer. Cancer. 1988 Nov 15;62(10):2183–2190. doi: 10.1002/1097-0142(19881115)62:10<2183::aid-cncr2820621019>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  15. Lykkesfeldt A. E., Balslev I., Christensen I. J., Larsen J. K., Mølgaard H., Rasmussen B. B., Thorpe S., Rose C. DNA ploidy and S-phase fraction in primary breast carcinomas in relation to prognostic factors and survival for premenopausal patients at high risk for recurrent disease. Acta Oncol. 1988;27(6A):749–756. doi: 10.3109/02841868809091780. [DOI] [PubMed] [Google Scholar]
  16. Meyer J. S., Province M. Proliferative index of breast carcinoma by thymidine labeling: prognostic power independent of stage, estrogen and progesterone receptors. Breast Cancer Res Treat. 1988 Oct;12(2):191–204. doi: 10.1007/BF01805940. [DOI] [PubMed] [Google Scholar]
  17. Moot S. K., Peters G. N., Cheek J. H. Tumor hormone receptor status and recurrences in premenopausal node negative breast carcinoma. Cancer. 1987 Aug 1;60(3):382–385. doi: 10.1002/1097-0142(19870801)60:3<382::aid-cncr2820600316>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  18. O'Reilly S. M., Camplejohn R. S., Barnes D. M., Millis R. R., Rubens R. D., Richards M. A. Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry. J Clin Oncol. 1990 Dec;8(12):2040–2046. doi: 10.1200/JCO.1990.8.12.2040. [DOI] [PubMed] [Google Scholar]
  19. O'Reilly S. M., Camplejohn R. S., Millis R. R., Rubens R. D., Richards M. A. Proliferative activity, histological grade and benefit from adjuvant chemotherapy in node positive breast cancer. Eur J Cancer. 1990;26(10):1035–1038. doi: 10.1016/0277-5379(90)90045-u. [DOI] [PubMed] [Google Scholar]
  20. Olsson H., Ranstam J., Baldetorp B., Ewers S. B., Fernö M., Killander D., Sigurdsson H. Proliferation and DNA ploidy in malignant breast tumors in relation to early oral contraceptive use and early abortions. Cancer. 1991 Mar 1;67(5):1285–1290. doi: 10.1002/1097-0142(19910301)67:5<1285::aid-cncr2820670502>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  21. Sigurdsson H., Baldetorp B., Borg A., Dalberg M., Fernö M., Killander D., Olsson H. Indicators of prognosis in node-negative breast cancer. N Engl J Med. 1990 Apr 12;322(15):1045–1053. doi: 10.1056/NEJM199004123221505. [DOI] [PubMed] [Google Scholar]
  22. Silvestrini R., Daidone M. G., Valagussa P., Di Fronzo G., Mezzanotte G., Bonadonna G. Cell kinetics as a prognostic indicator in node-negative breast cancer. Eur J Cancer Clin Oncol. 1989 Aug;25(8):1165–1171. doi: 10.1016/0277-5379(89)90410-0. [DOI] [PubMed] [Google Scholar]
  23. Spyratos F., Hacene K., Tubiana-Hulin M., Pallud C., Brunet M. Prognostic value of estrogen and progesterone receptors in primary infiltrating ductal breast cancer. A sequential multivariate analysis of 1262 patients. Eur J Cancer Clin Oncol. 1989 Aug;25(8):1233–1240. doi: 10.1016/0277-5379(89)90420-3. [DOI] [PubMed] [Google Scholar]
  24. Stål O., Brisfors A., Carstensen J., Ferraud L., Hatschek T., Nordenskjöld B. Interrelations between cellular DNA content, S-phase fraction, hormone receptor status and age in primary breast cancer. A series of 1,342 consecutively detected tumors. South-East Sweden Breast Cancer Group. Acta Oncol. 1992;31(3):283–292. doi: 10.3109/02841869209108174. [DOI] [PubMed] [Google Scholar]
  25. Stål O., Wingren S., Carstensen J., Rutqvist L. E., Skoog L., Klintenberg C., Nordenskjöld B. Prognostic value of DNA ploidy and S-phase fraction in relation to estrogen receptor content and clinicopathological variables in primary breast cancer. Eur J Cancer Clin Oncol. 1989 Feb;25(2):301–309. doi: 10.1016/0277-5379(89)90023-0. [DOI] [PubMed] [Google Scholar]
  26. Thorpe S. M. Immunological quantitation of nuclear receptors in human breast cancer: relation to cytosolic estrogen and progesterone receptors. Cancer Res. 1987 Apr 1;47(7):1830–1835. [PubMed] [Google Scholar]
  27. Thorpe S. M., Rose C., Rasmussen B. B., Mouridsen H. T., Bayer T., Keiding N. Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative primary breast cancer. Cancer Res. 1987 Nov 15;47(22):6126–6133. [PubMed] [Google Scholar]
  28. Toikkanen S., Joensuu H., Klemi P. The prognostic significance of nuclear DNA content in invasive breast cancer--a study with long-term follow-up. Br J Cancer. 1989 Nov;60(5):693–700. doi: 10.1038/bjc.1989.342. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Vindeløv L. L., Christensen I. J., Nissen N. I. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry. 1983 Mar;3(5):323–327. doi: 10.1002/cyto.990030503. [DOI] [PubMed] [Google Scholar]
  30. Wilking N., Rutqvist L. E., Nordenskjöld B., Skoog L. Steroid receptor levels in breast cancer. Relationships with age and menopausal status. Acta Oncol. 1989;28(6):807–810. doi: 10.3109/02841868909092312. [DOI] [PubMed] [Google Scholar]
  31. Wrange O., Nordenskjöld B., Gustafsson J. A. Cytosol estradiol receptor in human mammary carcinoma: an assay based on isoelectric focusing in polyacrylamide gel. Anal Biochem. 1978 Apr;85(2):461–475. doi: 10.1016/0003-2697(78)90243-9. [DOI] [PubMed] [Google Scholar]
  32. von Rosen A., Fallenius A., Sundelin B., Auer G. Nuclear DNA content in mammary carcinomas in women aged 35 or younger. Am J Clin Oncol. 1986 Oct;9(5):382–386. doi: 10.1097/00000421-198610000-00004. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES